Participate In Research

Liver Diseases6 Results found

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Principal Investigator

Eric M. Yoshida

Body Locations and Systems

Liver Diseases

Area

Vancouver

Age

18-85

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Principal Investigator

Eric M. Yoshida

Body Locations and Systems

Liver Diseases

Area

Vancouver

Age

18-75

Safety, Tolerability, and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in adults with primary biliary cholangitis (PBC).

Principal Investigator

Eric M. Yoshida

Body Locations and Systems

Liver Diseases

Area

Vancouver

Age

18-70 years

Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis (PSC-Phase 2)

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in adults with primary sclerosing cholangitis (PSC).

Principal Investigator

Eric M. Yoshida

Body Locations and Systems

Liver Diseases

Area

Vancouver

Age

18-70 years

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3)

The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.

Principal Investigator

Eric M. Yoshida

Body Locations and Systems

Liver Diseases

Area

Vancouver

Age

18-70

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4)

The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.

Principal Investigator

Eric M. Yoshida

Body Locations and Systems

Liver Diseases

Area

Vancouver

Age

18-70

Body Systems

Arteries (12)

Blood (25)

Heart (47)

Veins (1)

Bones (7)

Hip, Leg and Foot (8)

Joints (13)

Muscles (1)

Shoulder, Arm and Hand (1)

Spine (4)

Brain (88)

Spinal Cord (5)

Large Intestine (11)

Liver (28)

Small Intestine (10)

Ear (1)

Nose (1)

Throat (1)

Pancreas (18)

Thyroid (1)

Eye Disorders (15)

HIV (1)

Immune System and Disorders (6)

Bladder (4)

Kidney (22)

Lungs (28)

Men's Health (24)

Women's Health (26)

Mouth (1)

Skin Conditions (19)

Disorders and Conditions

Diagnosis and Therapy

Liver Diseases6 Results found

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Safety, Tolerability, and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2

Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis (PSC-Phase 2)

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3)

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4)

Subscribe to our mailing list